William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating today.
Sami Corwin’s rating is based on the promising developments observed in Tenaya Therapeutics’ clinical trial for TN-201. The data from the Phase Ib/II MyPeak-1 trial revealed consistent DNA and RNA expression in patients, which is a positive indicator of the therapy’s potential effectiveness. Notably, patient 2 exhibited a significant increase in TN-201 mRNA expression, which was substantially higher than that observed in patient 1, suggesting a strong therapeutic response.
Moreover, the MyBP-C protein expression data, although challenging to interpret fully due to limited follow-up, showed a slight increase in expression levels over time in patients 1 and 2. This consistency in protein expression, alongside the DNA and RNA findings, supports the potential of TN-201 as a viable treatment option, underpinning Corwin’s Buy rating for Tenaya Therapeutics’ stock.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $3.00 price target.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNYA in relation to earlier this year.